Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

NCT ID: NCT04085991

Last Updated: 2023-04-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-31
• Study Completion Date: 2023-01-15

Brief Summary

Single-arm, open-label, phase II trial in 200 competent adult male patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-3 and progressive metastatic prostate cancer, failing, failed, refused, not eligible for or no access to further approved lines of therapy. Patients will undergo sequential FDG positron emission tomography (PET) and 18F-DCFPyL PET to assess FDG/DCFPyL concordance fraction. Patients with DCFPyL/FDG concordance of 50% or greater will be treated with 131I-PSMA-1095 radioligand therapy (RLT). Best post-treatment serum prostate specific antigen response will be compared to concordance fraction.

Conditions

Prostate Cancer; Prostate Adenocarcinoma; Prostatic Neoplasms; Metastatic Prostate Cancer; Metastatic Prostatic Adenocarcinoma; Metastatic Prostate Carcinoma in the Soft Tissue

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

131I-PSMA-1095 Radioligand Therapy (RLT)

Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Group Type: EXPERIMENTAL

131I-PSMA-1095 Radioligand Therapy (RLT)

Intervention Type: DRUG

Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.

Interventions

131I-PSMA-1095 Radioligand Therapy (RLT)

Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.

Intervention Type: DRUG

Other Intervention Names

PSMA RLT

Eligibility Criteria

Inclusion Criteria

• Male
• Age 18 years or older
• Documented metastatic adenocarcinoma of the prostate
• Under active medical oncology care
• ECOG performance status 0 - 3, inclusive
• Able to understand and provide written informed consent
• Able to tolerate the physical requirements of two PET/CT scans including lying for up to 30 minutes
• Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the investigator
• Serum prostate specific antigen ≥ 1 ng/ml at baseline or CT/MRI soft-tissue measurable disease as per RECIST v1.1
• Failed, failing, refused, no access to or not eligible for any approved prostate cancer therapies including but not limited to: ADT, NAAD (e.g., abiraterone, enzalutamide, darolutamide or apalutamide), docetaxel, cabazitaxel, radium-223 and oligometastatic RTX
• Life expectancy of at least 3 months as judged by the investigator

Exclusion Criteria

• Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
• Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)
• Unmanageable claustrophobia
• Prior failure of PSMA RLT
• Prior hemi-body irradiation
• Impaired organ function as evidenced by any of the following laboratory values:

• Absolute neutrophil count < 1.5 x109/L
• Platelet count < 75 x109/L
• Hemoglobin < 85 g/L
• Albumin < 2.5 g/dL (25 g/L)
• Total bilirubin > 2 x ULN (unless in instances of Gilbert's disease)
• AST or ALT > 2.5 x ULN (or > 5.0 x ULN in the presence of liver metastases)

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Stephan Probst, MD

Chief of Nuclear Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stephan Probst, MD

Role: PRINCIPAL_INVESTIGATOR

Jewish General Hospital

Locations

Stephan Probst

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

CROSSBOW

Identifier Type: -

Identifier Source: org_study_id